The Board of Directors at its meeting held today i.e. August 16, 2025, have approved the allotment of 20,55,000 Equity shares of Rs. 10/- each upon conversion of 20,55,000 share warrants ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The board of Venmax Drugs and Pharmaceuticals approved the allotment of 20,55,000 equity shares (face value Rs. 10 each) upon conversion of an equal number of convertible warrants, originally allotted on March 20, 2025 on a preferential basis. The shares were issued at Rs. 20 each, comprising a Rs. 10 face value and Rs. 10 premium, to 15 non-promoter allottees (mostly individuals and a few small entities). The company received Rs. 3.08 crore as the balance 75% exercise price (Rs. 15 per warrant). Post-allotment, paid-up equity capital stands at Rs. 7.29 crore, comprising 72,93,930 shares. Of the original 1,00,25,000 warrants issued, 79,70,000 still remain outstanding for conversion.
This is a dilution event for existing shareholders, with the share count rising from around 52.4 lakh to 72.9 lakh shares (about 39% expansion from this tranche alone). The fact that only 20.5% of warrants have been converted so far suggests partial uptake and the possibility of further dilution if remaining warrants are eventually converted, which could weigh on the stock in the short term.